Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.

Choi, Michelle; Song, Jinlin; Bui, Cat N; Ma, Esprit; Chai, Xinglei; Yin, Lei; Betts, Keith A; Kapustyan, Tatyana; Montez, Melissa; LeBlanc, Thomas William

Choi, Michelle; Song, Jinlin; Bui, Cat N; Ma, Esprit; Chai, Xinglei; Yin, Lei; Betts, Keith A; Kapustyan, Tatyana; Montez, Melissa; LeBlanc, Thomas William.

Affiliation

Choi M; AbbVie Inc., North Chicago, IL.
Song J; Analysis Group, Los Angeles, CA.
Bui CN; AbbVie Inc., North Chicago, IL.
Ma E; Genentech, South San Francisco, CA.
Chai X; Analysis Group, Los Angeles, CA.
Yin L; Analysis Group, Los Angeles, CA.
Betts KA; Analysis Group, Los Angeles, CA.
Kapustyan T; AbbVie Inc., North Chicago, IL.
Montez M; Genentech, South San Francisco, CA.
LeBlanc TW; School of Medicine, Duke University, Durham, NC.

J Manag Care Spec Pharm ; 28(9): 980-988, 2022 Sep.

Article in En | MEDLINE | ID: mdl-35708343

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Induction Chemotherapy Type of study: Diagnostic_studies / Health_economic_evaluation / Systematic_reviews Aspects: Patient_preference Limits: Humans Language: En Journal: J Manag Care Spec Pharm Year: 2022 Document type: Article Affiliation country: Israel Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google